Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.

PloS one - 1 Jan 2014

Schou Jakob V, Rossi Simona, Jensen Benny V, Nielsen Dorte L, Pfeiffer Per, Høgdall Estrid, Yilmaz Mette, Tejpar Sabine, Delorenzi Mauro, Kruhøffer Mogens, Johansen Julia S

Abstract excerpt

INTRODUCTION: MicroRNAs (miRNAs) have important regulatory functions in cellular processes and have shown promising potential as prognostic markers for disease outcome in patients with cancer. The aim of the present study was to find miRNA expression profiles in whole blood that were prognostic f...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Disease-Free Survival

Share to Irinotecan

Share to Kaplan-Meier Estimate

Share to Proportional Hazards Models

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 24940606
DOI: 10.1371/journal.pone.0099886
PMCID: PMC4062472

Genes

KRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24940606-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.PMID 24940606Read ↗

The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs?Semantic proximity Read ↗

Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer.Semantic proximity Read ↗

Identification of A Four-Microrna Panel in Serum As Promising Biomarker for Colorectal Carcinoma DetectionSemantic proximity Read ↗

Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.Semantic proximity Read ↗

microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer.Semantic proximity Read ↗

MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAFSemantic proximity Read ↗

microRNA-34 family and treatment of cancers with mutant or wild-type p53 (Review).Semantic proximity Read ↗

High expression of microRNA‐625‐3p is associated with poor response to first‐line oxaliplatin based treatment of metastatic colorectal cancerSemantic proximity Read ↗

Combination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancerSemantic proximity Read ↗

MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signalingSemantic proximity Read ↗

Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal CancerSemantic proximity Read ↗

MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.